MARINOL 5 MG
DRONABINOL : 5 MG · DIN 00611204 · ABBOTT LABORATORIES, LIMITED
Health Canada status: CANCELLED POST MARKET
What is MARINOL?
MARINOL 5 MG contains DRONABINOL : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 00611204, held by ABBOTT LABORATORIES, LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 24-Feb-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MARINOL used for?
AIDS-related anorexia associated with weight loss; severe nausea and vomiting associated with cancer chemotherapy in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00611204 |
|---|---|
| Brand name | MARINOL |
| Generic / active ingredient | DRONABINOL : 5 MG |
| Manufacturer | ABBOTT LABORATORIES, LIMITED |
| Strength | 5 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A04AD10 DRONABINOL |
| AHFS class | 56:92.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 24-Feb-2012 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
AIDS anorexia: Initially 2.5 mg BID. Antiemetic: 5 mg/m2 1-3h before chemotherapy, then every 2-4h (4-6 doses/day). Titrate based on response and tolerability.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (referenced in section 16).
How is it supplied?
Not explicitly detailed in provided text (referenced in section 17).
Contraindications
Allergy to cannabinoids/sesame oil; hepatic/renal impairment; serious cardiovascular disease; history of schizophrenia/psychosis; children <18; pregnancy/nursing; women not on contraception.
Warnings and precautions
Potential for abuse/dependence. CNS effects (intoxication, impaired judgment). Cardiovascular effects (tachycardia, hypotension). Caution in patients with history of seizures or substance abuse.
What can be used instead?
Other Canadian products sharing ATC code A04AD10 DRONABINOL. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MARINOL | 2.5 MG | CAPSULE | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00611190 |
| MARINOL CAP 10MG | 10 MG | CAPSULE | SOLVAY PHARMA INC | CANCELLED POST MARKET | DIN 00611212 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.